ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$3.69+0.04 (+1.10%)
Close on Nov 18, 2026Market cap $366.96MP/E –Yield –
ARS Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
ARS Pharmaceuticals's pe ratio was 171.1× on Apr 30, 2025.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2025 | Apr 30, 2025 | 171.1× | +160.5 |
| 2023 | Jan 31, 2023 | 10.6× | −2.6 |
| 2022 | Dec 30, 2022 | 13.1× | – |
See a number that looks wrong?